Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance

Journal of Viral Hepatitis

Volumn 18, Issue 10, 2011, Pages

  Park, J W ^a   Kim, H S ^a   Seo, D D ^b   Jang, J S ^c   Shin, W G ^a   Kim, K H ^a   Jang, M K ^a   Lee, J H ^a   Kim, H Y ^a   Kim, D J ^a   Lee, M S ^a   Park, C K ^a  

^a Hallym University Medical Center   (South Korea)

^b Inje University   (South Korea)

^c Seoul Veterans Hospital   (South Korea)

Author keywords

adefovir; chronic hepatitis B; entecavir; lamivudine; multidrug resistance

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 80052847318     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01479.x     Document Type: Article

References (33)

1. Bosch FX, Ribes J, Cleries R, Diaz M,. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.
2. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)
3. Bartholomeusz A, Locarnini SA,. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-170. (Pubitemid 43668258)
4. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696. (Pubitemid 36337972)
5. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722. (Pubitemid 37500436)
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807. (Pubitemid 36245756)
7. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816. (Pubitemid 36245757)
8. Westland CE, Yang H, Delaney WE 4th, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12: 67-73. (Pubitemid 40188776)
9. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134. (Pubitemid 30432377)
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751. (Pubitemid 44958517)
11. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-758.
12. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-1495. (Pubitemid 44476796)
13. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-1391. (Pubitemid 43980117)
14. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010. (Pubitemid 43357804)
15. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020. (Pubitemid 43357805)
16. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009; 49: 72-79.
17. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
18. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-1341.
19. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
20. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-2049. (Pubitemid 43816960)
21. Suzuki F, Toyoda J, Katano Y, et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008; 23: 1320-1326.
22. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108. (Pubitemid 351975535)
23. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198-1209. (Pubitemid 41446860)
24. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937-943. (Pubitemid 41627977)
25. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F,. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-1261. (Pubitemid 44515103)
26. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009; 50: 1064-1071.
27. Zoulim F, Locarnini S,. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.
28. Lee JM, Kim HJ, Park JY, et al. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther 2009; 14: 705-712.
29. Cho SW, Koh KH, Cheong JY, et al. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepat 2010; 17: 171-177.
30. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ,. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53: 449-454.
31. van Bömmel F, Zöllner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325. (Pubitemid 44214870)
32. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
33. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60: 247-254.